Navigation Links
New Study Shows Impressive Results with Abutment-Free Sophono System
Date:2/7/2013

Boulder, Colo. (PRWEB) February 07, 2013

Children with the abutment-free, implantable bone conduction hearing device from Sophono, Inc., experienced significant improvement in hearing – without skin complications – according to a new study.

Sophono, Inc., is a Colorado-based medical device manufacturer. The Sophono Alpha System™ is the only abutment-free, implantable, bone-anchored hearing system on the market, treating those with conductive hearing loss, mixed hearing loss and single-sided deafness. Fitted to the patient’s head with the use of small, implantable magnets, the Sophono Alpha System eliminates the problems associated with other bone conduction hearing systems. These include drilling a hole in the patient’s skull and installing a very noticeable screw that pokes out through the skin on the side of the head.

The article summarizing the study findings, with preliminary results on how Sophono’s closed-skin bone-anchored implant worked in children with ear atresia, appears in the February issue of Otology & Neurotology. The study, conducted in Hôpital d’Enfants Armand-Trousseau (Paris Childrens’ Hospital) in 2012, evaluated the results of children between 6 and 9 years old. All had high-grade ear atresia, defined as the absence an external ear canal and resulting in the child’s inability to hear in the affected ear. A review of patient benefit at six months of use with the Sophono system showed that the children experienced the following.

1.    Hearing levels improved from severe conductive loss to nearly normal hearing.

2.    A high level of overall satisfaction – among both children and their parents

3.    No pain or skin complications

4.    Statistical and clinical improvement in speech-in-noise, an indication of how well the children could understand speech in a noisy environment

Study authors were: Françoise Denoyelle, M.D., Ph.D.; Nicolas Leboulanger, M.D., Ph.D.; Cyrille Coudert; Olivia Mazzaschi, M.D.; Natalie Loundon, M.D.; Eric Vicaut; Natacha Tessier; and Eréa-Noël Garabedian, M.D.

“The results that the article presents confirm the hearing performance Sophono continually sees with those using the Sophono Alpha System – in terms of hearing ability, speech understanding and high levels of satisfaction,” says Jim Kasic, president and CEO of Sophono. “Children, in particular, benefit from Sophono’s abutment-free technology.”

Sophono, Inc. (http://www.sophono.com)
Sophono, Inc., is a medical device manufacturer specializing in implantable, bone conduction hearing devices. The company’s products are designed for individuals suffering from severe to profound hearing loss or impairment. The Sophono Alpha 2™ System is the only abutment-free, implantable, bone-anchored hearing system available today. Treating those with conductive hearing loss, mixed hearing loss, and single-ear deafness, the FDA-cleared Alpha 2 device eliminates the problematic abutment of devices by using magnets to affix external sound processors.

Sophono corporate headquarters and manufacturing operations reside in Boulder, Colo. The company maintains an office in Germany, works with more than 20 distributors, and is actively selling in more than 30 countries.

(end)

Read the full story at http://www.prweb.com/releases/2013/2/prweb10405031.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. EU Study Finds UK Health Product Benefit Metric Flawed
2. Notre Dame study explores the potential benefits and threats of nanotechnology research
3. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
4. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
5. Wysebridge Launches Patent Bar Exam Study Review
6. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
7. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
8. Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics Human Pilot Study
9. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
10. Study identifies targeted molecular therapy for untreatable NF1 tumors
11. Study Finds Proof of Acupuncture Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):